Global Nanopharmaceuticals Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Nanopharmaceuticals market size was valued at US$ 40600 million in 2024 and is forecast to a readjusted size of USD 92900 million by 2031 with a CAGR of 12.7% during review period.
Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery. Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their “bulk” counterparts primarily because of size.
There are two types of nanopharmaceuticals: (1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier.
USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share.
The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share.
This report is a detailed and comprehensive analysis for global Nanopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Nanopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K MT), and ASP (USD/MT), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Nanopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Nanopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Nanopharmaceuticals market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Liposomes
Polymeric Micelles
Solid Lipid Nanoparticles
Microemulsion and Nnanoemulsion
Nanosuspension
Market segment by Application
Cancer and Tumor
Autoimmune Disorders
Inflammation
Others
Major players covered
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Nanopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Nanopharmaceuticals, with price, sales quantity, revenue, and global market share of Nanopharmaceuticals from 2020 to 2025.
Chapter 3, the Nanopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nanopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Nanopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Nanopharmaceuticals.
Chapter 14 and 15, to describe Nanopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery. Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their “bulk” counterparts primarily because of size.
There are two types of nanopharmaceuticals: (1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier.
USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share.
The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share.
This report is a detailed and comprehensive analysis for global Nanopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Nanopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K MT), and average selling prices (USD/MT), 2020-2031
Global Nanopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K MT), and ASP (USD/MT), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Nanopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Nanopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Nanopharmaceuticals market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Liposomes
Polymeric Micelles
Solid Lipid Nanoparticles
Microemulsion and Nnanoemulsion
Nanosuspension
Market segment by Application
Cancer and Tumor
Autoimmune Disorders
Inflammation
Others
Major players covered
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Nanopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Nanopharmaceuticals, with price, sales quantity, revenue, and global market share of Nanopharmaceuticals from 2020 to 2025.
Chapter 3, the Nanopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nanopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Nanopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Nanopharmaceuticals.
Chapter 14 and 15, to describe Nanopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
Table of Contents
147 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Nanopharmaceuticals by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
